Penn Pharma has successfully completed a recent FDA GMP inspection of its facility in South Wales, UK. The five-day inspection produced no 483s. The audit inspection focused on several of the company’s key service areas, such as manufacturing, analytical services, packaging/labeling and logistics. Mr. Mark Molyneux, chief executive officer and chairman of Penn Pharma said, “We are very pleased with the results of the recent FDA audit.It demonstrates our commitment to provide world-class...